NCT02243605 2026-04-13Cabozantinib S-malate in Treating Patients With Relapsed Osteosarcoma or Ewing SarcomaNational Cancer Institute (NCI)Phase 2 Active not recruiting90 enrolled 15 charts
NCT02867592 2026-04-13Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare TumorsNational Cancer Institute (NCI)Phase 2 Active not recruiting109 enrolled 24 charts